MIRA Pharmaceuticals, Inc. General and Administrative Expense
MIRA Pharmaceuticals, Inc. (MIRA) reported General and Administrative Expense of $450.33 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-08-12
- MIRA Pharmaceuticals, Inc. general and administrative expense for the quarter ending 2026-06-30 was $450.33K, a 57.11% decline year-over-year.
- MIRA Pharmaceuticals, Inc. general and administrative expense for the quarter ending 2026-03-31 was $578.70K, a 61.18% decline year-over-year.
- MIRA Pharmaceuticals, Inc. general and administrative expense for the quarter ending 2025-12-31 was $5.33M, a 238.01% increase year-over-year.
- MIRA Pharmaceuticals, Inc. general and administrative expense for the quarter ending 2025-09-30 was $904.35K, a 10.83% decline year-over-year.
- MIRA Pharmaceuticals, Inc. general and administrative expense for fiscal 2025 was $8.77M, a 86.16% increase from fiscal 2024.
- MIRA Pharmaceuticals, Inc. general and administrative expense for fiscal 2024 was $4.71M, a 27.49% decline from fiscal 2023.
- MIRA Pharmaceuticals, Inc. general and administrative expense for fiscal 2023 was $6.50M, a 117.22% increase from fiscal 2022.
- MIRA Pharmaceuticals, Inc. general and administrative expense for fiscal 2022 was $2.99M.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 6 month | General and Administrative Expense 9 month | General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $450.33K 10-Q · filed 2026-08-12 | $1.03M 10-Q · filed 2026-08-12 | $6.36M derived: sum of 3 quarters · filed 2026-08-12 | $7.26M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $578.70K 10-Q · filed 2026-05-14 | $5.91M derived: sum of 2 quarters · filed 2026-05-14 | $6.81M derived: sum of 3 quarters · filed 2026-05-14 | $7.86M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $6.23M derived: sum of 2 quarters · filed 2026-03-31 | $7.28M derived: sum of 3 quarters · filed 2026-08-12 | $8.77M 10-K · filed 2026-03-31 |
| 2025-09-30 | $904.35K 10-Q · filed 2025-11-13 | $1.95M derived: sum of 2 quarters · filed 2026-08-12 | $3.45M 10-Q · filed 2025-11-13 | $5.02M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.05M 10-Q · filed 2026-08-12 | $2.54M 10-Q · filed 2026-08-12 | $4.12M derived: sum of 3 quarters · filed 2026-08-12 | $5.13M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.49M 10-Q · filed 2026-05-14 | $3.07M derived: sum of 2 quarters · filed 2026-05-14 | $4.08M derived: sum of 3 quarters · filed 2026-05-14 | $5.20M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.59M derived: sum of 2 quarters · filed 2026-03-31 | $3.71M derived: sum of 3 quarters · filed 2026-03-31 | $4.71M 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.01M 10-Q · filed 2025-11-13 | $2.13M derived: sum of 2 quarters · filed 2025-11-13 | $3.14M 10-Q · filed 2025-11-13 | $5.81M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.12M 10-Q · filed 2025-08-14 | $2.12M 10-Q · filed 2025-08-14 | $4.79M derived: sum of 3 quarters · filed 2025-08-14 | $6.94M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.01M 10-Q · filed 2025-05-14 | $3.68M derived: sum of 2 quarters · filed 2025-05-14 | $5.82M derived: sum of 3 quarters · filed 2025-05-14 | $6.89M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $4.81M derived: sum of 2 quarters · filed 2025-03-28 | $5.89M derived: sum of 3 quarters · filed 2025-03-28 | $6.50M 10-K · filed 2025-03-28 |
| 2023-09-30 | $2.14M 10-Q · filed 2024-11-12 | $3.22M derived: sum of 2 quarters · filed 2024-11-12 | $3.83M 10-Q · filed 2024-11-12 | $3.88M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.07M 10-Q/A · filed 2024-08-16 | $1.69M 10-Q/A · filed 2024-08-16 | $1.74M derived: sum of 3 quarters · filed 2024-08-16 | $2.47M derived: sum of 4 quarters · filed 2024-08-16 |
| 2023-03-31 | $614.24K 10-Q · filed 2024-05-13 | $665.89K derived: sum of 2 quarters · filed 2024-05-13 | $1.40M derived: sum of 3 quarters · filed 2024-05-13 | $2.99M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $51.66K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $787.72K derived: sum of 2 quarters · filed 2024-04-01 | $2.38M derived: sum of 3 quarters · filed 2024-04-01 | $2.99M 10-K · filed 2024-04-01 |
| 2022-09-30 | $736.06K 10-Q · filed 2023-11-13 | $2.33M derived: sum of 2 quarters · filed 2023-11-13 | $2.94M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $1.59M 10-Q · filed 2023-09-15 | $2.20M 10-Q · filed 2023-09-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |